ViroPharma

Shire to file Vyvanse for binge-eating in Q3

The Viropharma deal - which closed last month - brings in an already-marketed drug for hereditary angioedema with sales running at around $100m a quarter last year. ... After a strong performance in 2013, and the completion of the ViroPharma acquisition,

Shire's ADHD drug fails in depression trial

This includes a restructure of its pipeline, as announced in November last year, as well as the £2bn purchase of rare disease specialist ViroPharma.

Pharma deals during November 2013

acquisitions. Following the rumours that had abounded over the last few months, the top of the table deal this month was the acquisition of ViroPharma, the orphan drugs company by Shire. ... In 2012 ViroPharma generated revenues of $428m, with Cinryze

Shire snaps up Viropharma to build $2bn rare disease unit

Gains access to Cinryze in expensive but 'strategically sound' deal. Shire has signed a deal to buy US company ViroPharma for around $4.2bn as it continues to build its portfolio ... The $50-per-share cash offer has been approved by both companies' board

Pharma deals during September 2013

Alexion, Biomarin and ViroPharma have all been under the spotlight this month as speculation shifts from large Pharma looking to get in on the action or an existing niche player making

[ Previous 5 results ] 1 2 3 4 5 6 7 [ Next 5 results ]